Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment halted in INSPIRE trial of necitumumab in advanced NSCLC

Feb. 3, 2011

Rituxan approved in U.S. for first-line maintenance use in follicular lymphoma

Jan. 31, 2011

MorphoSys receives milestone payment from OncoMed Pharma for phase I OMP-59R5 trial

Jan. 31, 2011

Generex to modify enrollment in phase II AE-37 trial in breast cancer

Jan. 26, 2011

Amgen to acquire BioVex and its oncolytic vaccine OncoVEX(GM-CSF)

Jan. 26, 2011

TRU-016/bendamustine combination enters phase Ib/II trial in CLL

Jan. 26, 2011

Enrollment resumed in phase II DCVax-Brain trial in glioblastoma multiforme

Jan. 26, 2011

Phase II trial of ADXS-11-001 in cervical dysplasia advances

Jan. 18, 2011

Vaximm obtains funding for phase I testing of VXM-01 vaccine

Jan. 18, 2011

OncoMed begins phase I trial of OMP-59R5 in advanced solid tumors

Jan. 17, 2011

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...